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Summary: A 3D Printed swab was invented to address supply chain disruptions caused by
COVID-19 resulting in shortages of the standard synthetic nasopharyngeal swab used for
SARS-COV-2 testing. A clinical trial compared the novel 3D printed swab against the
synthetic swab.

Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus
that causes COVID-19, can be detected in respiratory samples by Real-time Reverse
Transcriptase (RT)-PCR or other molecular methods. Accessibility of diagnostic testing for
COVID-19 has been limited by intermittent shortages of supplies required for testing,
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including flocked nasopharyngeal (FLNP) swabs.
Methods: We developed a 3D-printed nasopharyngeal (3DP) swab as a replacement of the
FLNP swab. The performance of 3DP and FLNP swabs were compared in a clinical trial of
symptomatic patients at three clinical sites (n=291) using three SARS-CoV-2 EUA tests: a
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modified version of the CDC Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel
and two commercial automated formats, Roche Cobas and NeuMoDx.

M

Results: The cycle threshold (C(t)) values from the gene targets and the RNase P gene

d

control in the CDC assay showed no significant differences between swabs for both gene
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targets (p=0.152 and p=0.092), with the RNase P target performing significantly better in the
3DP swabs (p < 0.001). The C(t) values showed no significant differences between swabs for
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both viral gene targets in the Roche cobas assay (p=0.05 and p=0.05) as well as the
NeuMoDx assay (p=0.401 and p=0.484). The overall clinical correlation of COVID-19

Ac

diagnosis between all methods was 95.88% (Kappa 0.901).
Conclusions: 3DP swabs were equivalent to standard FLNP in three testing platforms for
SARS-CoV-2. Given the need for widespread testing, 3DP swabs printed on-site are an
alternate to FLNP that can rapidly scale in response to acute needs when supply chain
disruptions affect availability of collection kits.
Keywords: SARS-CoV-2, COVID-19, 3D-printed swabs, molecular diagnostics,
nasopharyngeal

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes
coronavirus disease 2019 (COVID-19), was first described in December 2019, in Wuhan,
China and quickly spread globally. The World Health Organization (WHO) confirmed, 282
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cases on January 20, 2020 and, as of June 30, 2020, confirmed over seven million cases[1],
causing over ~500,000 deaths according to the database from the Center for System Science
and Engineering (CSSE) at Johns Hopkins University.[2, 3]

SARS-CoV-2, the seventh coronavirus known to be transmitted between humans, has

an

shown high transmission rates and is stable on surfaces and in aerosols.[4-6] Symptoms of
COVID-19 range from mild to severe respiratory illness, with cough, fatigue, and fever being

M

common. It is a progressive and severe disease in certain individuals. Those with underlying
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medical conditions and the elderly are most at risk of developing more severe disease.[4] In
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addition, high levels of SARS-CoV-2 shedding in the upper respiratory tract has been
reported, even in asymptomatic patients,[7, 8] making individual testing to identify viral
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carriage even more critical for infection control. Initially, there were no available therapeutics
approved for treatment or prevention of COVID-19 [9], however the investigational drug
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remdesivir received emergency use authorization on May 1, 2020 by the US Food and Drug
Administration (FDA).[10] Containment depends on wide-spread testing, isolation of positive
cases, and contact tracing.[11] The gold standard for testing respiratory viruses, including
SARS-CoV-2, is collection from a patient’s nasopharynx (NP) using a standard flocked NP
swab (FLNP).[12]

COVID-19 diagnostic testing has expanded exponentially in an international effort
fighting the pandemic. However, disruption in the medical supply chain[13] caused by this
crisis resulted in test kit shortages, including FLNP swabs.[14] Furthermore, initial phases of
the SARS-CoV-2 pandemic coincided with influenza season in many locations, compounding
supply chain issues. NP swab global utilization relies on a limited number of manufacturers,
who require significant lead time to ramp up production, and created major barriers to testing
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and containment of the disease. To address supply shortfalls, 3D printing is an effective
stopgap technology for medical devices and supplies.[15] To combat critical NP swab

shortages, we designed and clinically evaluated a 3D-printed swab (3DP) alternative to the
FLNP swab used for nasopharyngeal sample collection.
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Methods

M

3D-Printed Swab Design and collection kits

The 3D-printers selected for 3DP swab manufacturing were the Form2 and Form 3B

d

(Formlabs, USA) due to pre-existing validation and FDA-cleared workflows using an
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autoclavable surgical grade resin (Surgical Guide, FormLabs) manufactured in an ISO 13485
certified facility. A detailed methodology used to develop the 3DP swab is available in an
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article in the journal, 3D Printing in Medicine by Ford et al. [16] These printers are relatively
affordable and ubiquitous in hospitals that maintain their own 3D printing labs. Also critical

Ac

to the viability of this alternative swab, the surgical guide resin is manufactured in the US by
FormLabs and the supply was deemed stable to ensure access to raw materials.

Because clinical sites had difficulties obtaining commercially supplied collection kits,
3DP swabs were usually provided with collection media in collection kits assembled inhouse. Amongst the media used were WHO approved viral transport media,[17] in-hospital
manufactured VTM following the Centers for Disease Control and Prevention (CDC)

recommended procedure for preparation of VTM (CDC SOP# DSR-052-03) [18] or, when
available, either VTM or Universal Transport Media provided by commercial manufacturers
(BD). In-hospital VTMs were manufactured and validated on-site and were accepted by our
CLIA laboratories. Individual 3DP swabs were placed in peel-packs along with sterilization
indicators and autoclaved. If needed, VTM collection media was packaged in sterile aliquots
of 1.5 or 3 ml and provided as collection kits. Sites were also given detailed protocols so that
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they could produce collection kits on-site.[16]

Bench Lab Testing

To validate sample collection, the 3DP swab was first compared against the FLNP
equivalent using respiratory syncytial virus (RSV) as a surrogate RNS virus. 1 ml of synthetic
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sputum[19] was spiked with 106 plaque-forming units (PFU) of RSV. FLNP and 3DPS were
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dipped in sputum and rotated for 5 seconds. Tips were cut off into 1 ml of BD universal
transport media (UTM). Each tip was incubated in UTM for 15 minutes at 22° C. 140 µl

d

UTM from each tube was subjected to RNA isolation with Qiagen viral RNA mini kit,
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elution in 50 µl. 10 µl of RNA was used to make cDNA (iScript, BioRad) in a 20 ml final
volume. A qRT-PCR was performed with 2 sets of RSV primers for the N gene (RSV N

ce

Forward: AAGGGATTTTTGCAGGATTGTTT, RSV N Reverse:
CTCCCCACCGTAGCATTACTTG) and the SH-G intergenic region (RSV SH-G Forward:
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TTAACATCCCACCATGCAAA, RSV SH-G Reverse: GCATTTGCCCCAATGTTATT). 2
µl of cDNA per well, in triplicate wells, was used in a 20 µl qRT-PCR reaction using
SensiFAST SYBRgreen kit (Bioline). Cycle thresholds (C(t)) were recorded for RSV RNA
detection.
Leeching tests were performed to ensure 3DPS stability after sterilization and to
ensure swab materials did not interfere with downstream testing. BD UTM was spiked with

RSV (106 PFU/ml) and aliquoted (1 ml) into 1.8 ml cryotubes. Triplicate tubes either
contained a sterile 3DPS tip or was left swab-less and incubated at 4° C. Samples (140 µl)
harvested at 24, 48 and 72 hours and subjected to RNA isolation and qRT-PCR as above.
Clinical testing
The clinical trial was approved by Western IRB for all sites under an umbrella
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protocol (No. 20200779). Participants (N=291) presenting for COVID-19 testing were
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verbally consented by health care providers. Three different medical centers participated in
this initial study. Dual paired swabs (FLNP and 3DPS) were collected from each participant
following CDC guidelines on COVID-19 NP collections. FLNP and 3DP swab order was not
systematically tested. One swab, be it FLNP or 3DP, was used per nostril. The left or right
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nostril order was randomly selected. All sites printed and processed their own 3DP swabs.
Site 1 (Northwell) samples were processed using a modified version of the CDC 2019-Novel

M

Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic EUA Panel with the N1, N2, and

d

RNase P gene targets.[20] Site 2 (USF-Tampa General Hospital) samples were processed
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using the CDC assay and the automated Neumodx Sars-CoV-2 Assay (NeuMoDx Molecular
Systems) which targets viral nonstructural protein 2 (NSP 2) and the N gene.[21] Samples
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were reported positive if either target was detected. Samples were reported negative if both
targets were not detected. A sample was reported as indeterminate if repeated testing did not
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return as result. Site 3 (Thomas Jefferson University Hospital) samples were also processed
using the CDC assay (subset samples for RNAseP only) and the automated Cobas 6800
SARS-CoV-2 assay, which targets the SARS-CoV-2 open reading frame 1 (ORF1) and the E
gene (Roche).[22] A sample was reported positive if both targets (ORF1 and E) or only
ORF1 was detected, and as presumptive positive if only E was detected. A sample was
reported negative if both targets were not detected. Samples were recorded as positive,
negative or inconclusive and used to calculate agreement between FLNP and 3DP swabs.

Statistical analysis
For bench lab testing, measures of central tendency were calculated for swab RSV
detection as well as leeching. For clinical testing statistics, Wilcoxon Signed Rank Tests were
conducted for C(t)s for both COVID-19 gene targets for positive cases for every testing
platform. For CDC assays, RNase P (RP) were also compared via Wilcoxon Signed Rank
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coefficient was also calculated to measure FLNP and 3DP agreement.
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Tests. A p-value ≤ 0.01 was considered statistically significant. Percent agreement and Kappa

Results
3D swab design

Conventional FLNP are used for sampling the NP, requiring enough flexibility to
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access the NP while collecting sufficient material for diagnostic testing. Materials such as
wood or cotton inhibit PCR reactions. The material used must be safe for humans, yet not
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inhibit down-stream diagnostic testing. The 3DP swab underwent several iterations before
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establishing a final design. Flocked swab geometry was referenced to influence ultimate 3DP
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design. Other influences included patient comfort, surface area maximization and the selected
3D-printer’s capabilities.
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Initial CAD 3DP swab drawings were created in 3-matic (Materialise) with a “cattail”
tip design, a rounded nose for patient comfort and lateral alternating nubs to maximize

Ac

surface area. The total swab length is 150 mm, with a tip length of 15 mm and a 3.85 mm
diameter. The neck is 20 mm in length with 1.5 mm in diameter and the shaft is 2.45 mm in
diameter with a break-point at 70 mm, dimensions which meet most test tube requirements.
The swab is printed without supports with 324-380 per batch (Figure 1). 3DP swab were
tested for safety and comfort using volunteers. An independent study compared
complications using the standard synthetic flocked swab and the 3DP swab and found they
performed equally.[23]

Bench lab testing
To verify the swab material and collection kit VTM did not inhibit PCR reactions,
initial lab testing was performed using a validated qRT-PCR assay RSV. It was not possible
to directly test the stability of SARS CoV-2 due to lack of access to either a BSL3 facility or
live virus. However, RSV is an enveloped RNA virus with a helical nucleocapsid and is
biochemically very similar to SARS CoV-2. We used the standard WHO VTM recipe for
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human samples containing viruses, chlamydia and mycoplasma. Pilot studies examining the
qRT-PCR assay sensitivity on RSV in VTM showed that 106 PFU/ml gave the best dynamic
range to detect changes in viral RNA in the sample. Therefore, the 3D printed swab was
tested with this concentration. For swab performance, C(t) values for RSV genome (SH-G)

an

[7.23 ± 1.18 versus 8.04 ± 0.14 (p = 0.3, N = 3), 3DPS and FLNP, respectively] and N gene
[5.89 ± 0.49 and 9.06 ± 0.70 (p < 0.01, N = 3), 3DPS and FLNP, respectively] were similar.

M

In clinical labs, patient samples can be tested for up to 3 days after collection, so we
determined the stability of the 3DPS over 3 days. 3DP leeching tests had C(t) values of RSV
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N gene for days 1, 2 and 3 were 25.00 ± 0.32, 25.42 ± 0.21, and 24.96 ± 0.58, respectively.
Control (swabless vials) C(t) values for days 1, 2 and 3 were 24.79, 25.41 and 24.59
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respectively.
Clinical testing
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We tested both negative and positive samples at 3 different trial sites in 291 adults

(age range 14-94) presenting to our emergency rooms or inpatients requiring SARS-CoV-2
testing (Table 1). CDC assay positive tests where PCR results for both gene targets matched
(N = 51) showed no significant differences between FLNP and 3DP for either the N1 (FLNP
C(t), 27.25 ± 6.02 3DP C(t), 27.85 ± 6.12) or N2 (FLNP C(t), 27.47 ± 5.91 C(t), 28.16 ±
6.18) viral gene targets (p=0.18, p=0.103 respectively). The 3DP performed significantly
better for RNase P gene target detection with FLNP 26.03 ± 1.16, and 3DP 25.57 ± 1.12, (N

= 104, p <0.001). Results for the Roche Cobas assay where both gene targets matched (N =
11) showed no significant differences between FLNP and 3DP for either the ORF1 (FLNP
C(t), 22.18 ± 6.02 3DP C(t), 23.26 ± 5.2) or E gene (FLNP C(t), 22.85 ± 5.55 C(t), 23.91 ±
5.63) viral gene targets (p=0.05, p=0.05 respectively). NeuMoDx assay positive tests where
both gene targets matched (N = 8) showed no significant differences between FLNP and 3DP
for either the NSP2 (FLNP C(t), 25.58 ± 6.36 3DP C(t), 26.64 ± 6.59) or N gene (FLNP C(t),
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26.74 ± 6.41 C(t), 27.63 ± 6.29) viral gene targets (p=0.401, p=0.484 respectively). These
results are graphically displayed in Figure 2A, B and C with numeric agreement in Tables 2,
3 and 4.

Overall clinical correlation of COVID-19 diagnosis between the two swabs was
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95.88% (279/291) with Kappa = 0.901, a high level of agreement.[24] A detailed breakdown
of the combined FLNP and 3DP swab agreement is in Table 5. Half of cases where swab

M

results disagreed were inconclusive (i.e. a result could not be reported by the lab) and in a
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clinical setting would require patient resampling (6 times). There were two cases where the
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FLNP sample was positive but the 3D swab was negative. There were four cases where the
FLNP sample was negative but the 3D swab was positive. In general, discordant cases were

ce

ones where C(t) values were high and less viral material was detectable. Throughout the
trial’s course, scant nasal bleeding after completion of both swabs was reported but no

Ac

clinical intervention was needed in any of those cases and no other adverse reactions or
breakage of either FLNP or 3DP swabs were reported.
Discussion
The SARS-CoV-2 pandemic created a burden on healthcare systems worldwide and
interrupted supply chains used to fight against COVID-19. Diagnostic testing is critical to the
response to the novel coronavirus. Current business models operate on “just-in-time” supply
chain models, relying upon readily available supplies and delivery. Thus, stockpiling reagents

and supplies is atypical. Unfortunately, this efficient business model for production of FLNP
swabs was disrupted by the SARS-CoV-2 health crisis, and manufacturers were unable to
respond to the sudden world-wide surge in demand for FLNP.

3D-printed technology provides an alternate strategy for swab shortages by
facilitating a local solution to FLNP shortages. The 3DPS displayed statistically identical

t

results to standard FLNP in a head-to-head clinical trial, making it a viable option in testing
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for SARS-CoV-2 infections. The 3DP, which has a more rigid brush-like head compared to
the standard FLNP, likely collected additional epithelial cells which may increase sensitivity
in sample collections as seen by the 3DPS RPP gene C(t) values, which were significantly
better than standard FLNP swabs. The fact that the FLNP and 3DPS comparison results were
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the same using three different assay methods (CDC assay, NeuMoDx and Roche Cobas)

M

illustrates that the 3DP can be used reliably across platforms. At the time of this publication,

d

Northwell Health moved to the Panther System (Hologic) for their clinical testing.
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The 3DP swab was innovated to offset standard FLNP shortages not only at our local
facilities but with the intention to share the design with any site throughout the world where

ce

3D printer capabilities may be established. As 3D-printing allows for design alterations to be
rapidly put into production, several iterations in swab design have been created and readily

Ac

available by partner institutions. For example, the current swab being produced by Northwell
contains a brush diameter that is 10% smaller compared to the USF swab. Furthermore,
several other groups have utilized 3DP swabs in place of FLNP swabs. One group examined
160 designs from 48 different materials from 48 manufacturers, focusing on four designs in a
clinical trial.[25] One of their main findings was to balance tip design to maximize surface
are while balancing it for patient comfort. 3D printing technologies used in that clinical trial
are not as readily available as the Form 2/Form 3B printer utilized in this study.

Additionally, material costs of an individual 3DP swab ranges from $0.25-$0.46
depending on whether an institution has an in-house printing team and sterile processing unit
with the necessary equipment and materials. Comparatively, commercial FLNP swabs cost
approximately $1.00 per unit. Regarding the effort required to print and process 3DP swabs,
sites were able to shift staff with available extra capacity due to decreased workloads caused
by a decrease in surgical caseloads. This further illustrates the role the 3DP swab can play in
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filling the supply gap that is cost efficient and rapidly deployable. The initial cost of a
Formlabs system is approximately $3,600 (Form 2) to $6,000 (Form 3B). This includes
washing and curing stations for post processing. Each Surgical Guide resin cartridge is $249.
Print times range from 11-15 hours per batch.
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Our clinical trial showed that 3DP swabs were an efficient and reliable alternative to
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standard FLNP swabs. The data supports the feasibility of medical teams across the US to
deploy 3DP swabs at local sites allowing for rapid local production and distribution that can
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utilize the same production designs and protocols, facilitating supply maintenance and data
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comparison. FLNP swabs are also routinely used to collect nasopharyngeal samples testing
for other respiratory viruses including influenza and RSV. Our preliminary results suggest

ce

that 3DP may be used for diagnosis of other respiratory viruses, but our clinical study was
conducted when the incidence of these infections was low in our respective geographic
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regions, so future studies will need to be conducted to evaluate whether 3DP swabs can be
used for all indications that FLNP swabs are used. If so, it is possible that 3DP swabs may be
deployed in under resourced or remote settings to enable local manufacturing of swabs.

Some study limitations include sample size and lack of pediatric testing. As this study
was developed in response to a critical shortage of testing swabs, our hospitals were unable to
provide large FLNP swab samples to be used for clinical trial. Once we were able to

demonstrate the validity of the clinical results, the data was presented to the hospitals’
advisory committees and were accepted as standard of care swabs due to the crisis.
Additionally, this trial focused on adults. While a pediatric version of the swab was created,
the current clinical trial only included one subadult.

As a result of this study, all three sites and others participating in our clinical trial

t

have moved forward using 3DP swabs as the alternate to the standard of care swab in patient
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testing when commercial swabs and kits are not available. As demand for swabs increases,
validated designs, such as the one described here, can be designed on multiple printing
platforms, assisting healthcare facilities worldwide with diagnosis testing for SARS-COV-2.
In addition, combining in-house UTM production[17, 18] and 3DP swabs may provide an
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effective, cost-efficient, and fast alternative to standard FLNP and viral transport media kits
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while increasing testing capabilities.

M

used for COVID-19 testing and with the potential to alleviate a major supply chain hurdles,
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Table 1: Site Demographics
Male
47
45
43

Female
57
56
43

Age Range
14-86
20-86
19-94
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Site
Northwell Health
Jefferson Health
Tampa General Hospital

Table 2: Table of Agreement for CDC Assay
3DP

3DP

3DP

Total

+

-

inconclusive

+

54

0

2

56

FLNP

-

2

50

0

52

FLNP

inconclusive

0

2

0

2

56

52

2

110

us
cr
ip

Total
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* 94.55% Agreement, Kappa 0.895
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t

FLNP

Table 3: Table of Agreement for Roche Cobas
3DP

3DP

3DP

Total

+

-

inconclusive

+

11

2

0

13

FLNP

-

1

87

0

88

FLNP

inconclusive

0

0

0

0

12

89

0

101
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Total
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* 97.03% Agreement, Kappa 0.863
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Table 4: Table of Agreement for NeuMoDx
3DP

3DP

3DP

Total

+

-

inconclusive

+

9

0

1

10

FLNP

-

1

66

1

68

FLNP

inconclusive

0

0

2

2

10

66

4

80
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ip

Total
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* 96.25% Agreement, Kappa 0.867
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FLNP

Table 5: Table of Agreement for All Methods
3DP

3DP

3DP

Total

+

-

inconclusive

+

74

2

3

79

FLNP

-

4

203

1

208

FLNP

inconclusive

0

2

2

4

78

207

6

291
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ip

Total
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* 95.88% Agreement, Kappa 0.901
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t

FLNP

Figures and Figure Legends

Figure 1. 3D Model of 3DP swabs and two batches of 324 swabs
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Figure 2. Graphical comparisons of the FLNP and 3DP C(t) targets for A) CDC Assay,
B) Roche Cobas and C) NeuMoDx.
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